| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc. | NRX-101 | Post-traumatic stress disorder (PTSD) | Phase 2 | Trial Planned | Oral | Psychiatric |
| NuCana plc | NUC-1031 (Acelarin) | Pancreatic cancer | Phase 3 | Intravenous | Oncology | |
| NuCana plc | Acelarin (NUC-1031) + Cisplatin - (NuTide:121) | Advanced biliary tract cancer | Phase 3 | Intravenous | Oncology | |
| NuCana plc | NUC-3373 (NuTide: 323) | 2L Colorectal cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| NuCana plc | NUC-1031 (Acelarin) | Platinum-sensitive ovarian cancer | Phase 2 | Intravenous | Oncology | |
| Nurix Therapeutics Inc. | Bexobrutideg - (DAYBreak CLL-306) | Relapsed or refractory chronic lymphocytic leukemia (CLL) | Phase 3 | Trial Planned | Oral | Oncology |
| Nurix Therapeutics Inc. | Bexobrutideg - (DAYBreak-CLL-201) | Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | Enrollment Initiation | Oral | Oncology |
| Nuvalent Inc. | Zidesamtinib (NVL-520) - (ARROS-1) | ROS1 Non-small cell lung cancer (NSCLC) | PDUFA | Data Released | Oral | Oncology |